Parallel Bio
Using the immune system to cure disease
About
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. Based in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.
Founders
- Robert DiFazio
- Juliana Hilliard
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Parallel Bio.
See family office activity